Spain Opioid Induced Constipation Market Size, Share, Industry, Forecast and outlook (2023-2030)
Spain Opioid-Induced Constipation Market is segmented By Drug class (Mu-Opioid Receptor Antagonists (Naldemedine, Naloxegol, Methylnaltrexone), Chloride Channel Activators (Lubiprostone)), By Mode of administration (Oral, Parenteral), By Distribution channel (Hospital Pharmacies, Online pharmacies, Retail pharmacies), and By Region – Share, Size, Outlook, and Opportunity Analysis, 2022-2029.
Spain Opioid Induced Constipation Market is expected to grow at a high CAGR 4.4% during the forecasting period (2022-2029).
Spain Opioid-Induced Constipation Market
|
Metrics |
Details |
|
Market CAGR |
4.4% |
|
Segments Covered |
By Drug class, By Mode of administration, By Distribution channel, and By Region |
|
Report Insights Covered |
Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
|
Fastest Growing Region |
Asia Pacific |
|
Largest Market Share |
North America |
Get A Free Sample Click Here
Opioids are effective for treating and managing pain, but using them frequently can lead to constipation. This can affect a person's comfort, health, and quality of life. According to an article in the BMJ, among people who use opioids for pain relief, constipation affects 52 % of those with advanced cancer and 87 % of the according to an article in the BMJ, among a terminal illness.
Spain Opioid-Induced Constipation Market Dynamics
The major driving forces used constipation, recent drug approvals and robust pipeline, and rising opioids for chronic pain.
The rising prevalence of opioid-induced constipation is expected to boost the market. For instance, Opioid consumption in Spain has increased by 84% from 2008 to 2015, moving from 7.25 Defined Daily Doses/1000 inhabitants/day in 2008 to 13.31 Defined Daily Doses/1000 inhabitants/day in 2015. Although opioids are highly efficacious for treating acute and chronic pain, they can also cause several significant side effects. One of the most commonly reported side effects of opioid use is opioid-induced constipation. According to the Journal of Pain and Symptom Management, in 2018, around 30% of the population of Spain who was prescribed opioid drugs experienced constipation due to drug consumption. Thus, the increasing prevalence of opioid-induced constipation is driving the market.
The presence of recent drug approvals and the key strategies by the market players are expected to boost the market. For instance, a few of the drugs that have gained recent approval for the treatment of opioid-induced constipation are Naldemedine, manufactured by Shionogi Inc. and got FDA and EMA approval in 2017 2019, respectively. In the US market, Shionogi Inc. has partnered with Purdue Pharma in a joint venture for US commercialization of Symproic (Naldemedine) in 2017. In June 2019, Shionogi and Ferrer announced an exclusive promotion agreement for RIZMOIC® (naldemedine) in Spain for the treatment of opioid-induced constipation (OIC) in adult patients previously treated with a laxative. Thus, recent drug approvals and the key strategies by the market players are driving the market.
The rising consumption of opioids for chronic pain is expected to boost the market growth over the forecast period. For instance, according to European Monitoring Centre for Drugs and Drug Addiction, in 2019, 68,297 people in Spain were high-risk opioid users. Also, there is a rise in the number of cancer cases in Spain. According to the Spanish Society of Medical Oncology, there is 15% in Spain cases from 2012 to 2017. Thus, the increasing consumption of opioids for chronic pain in Spain is Spain's casesid-induced constipation market.
However, a low diagnosis rate and stiff competition from standard laxatives are restraining the market's growth.
The low diagnosis rate is likely to hamper the market. For instance, there is a lack of awareness among clinicians about opioid-induced constipation in patients on opioid therapy in Spain, one of the major factors hampering the growth of the opioid-induced constipation market. Even if the clinicians are aware, they generally do not ask patients questions about constipation. Usually, patients might feel ashamed to disclose their constipation-related symptoms to clinicians. The major restraint that is hampering the market's growth is the absence of universal diagnostic criteria for opioid-induced constipation. The efforts to screen pat market's growth is the criteria may not cover the whole spectrum of OIC that might present with abdominal pain.
Spain Opioid-Induced Constipation Market Segmentation
The Spain opioid-induced constipation market can be segmented by drug class into Mu-Opioid Receptor Antagonists (including PAMORAs) and Chloride Channel Activators.
The Mu-Opioid Receptor Antagonists is expected to grow at a high rate over the forecast period. Mu-Opioid Receptor Antagonists (including PAMORAs) are designed to antagonize the intestinal activity of opioids while preserving their systemic effect. Some of the Mu-Opioid Receptor Antagonist drugs include Naldemedine, Naloxegol, and Methylnaltrexone.
The Naldemedine segment is expected to drive the market over the forecast period, owing to recent FDA approvals. Naldemedine is one of the key peripherally acting mu‐opioid receptor antagonists manufactured by Shionogi as a once‐daily treatment of OIC. Most recently, in February 2019, naldemedine was approved by EMA for the treatment of opioid-induced Constipation Treatment (OIC) in adult patients who have previously been treated with a laxative. In May 2019, Shionogi and Molteni concluded a contract for the distribution and sale of RIZMOIC to treat OIC in adult patients previously treated with a laxative in the two key European markets, Italy and Poland. Thus, the presence of recent FDA-approved drugs is driving the market.
The Spain opioid-induced constipation market can be segmented by mode of administration into oral and parenteral.
The oral segment is expected to grow at a high rate over the forecast period, owing to approved oral drugs for opioid-induced constipation treatment. For instance, in October 2016, Valeant and Progenics Pharmaceuticals launched an oral formulation of methylnaltrexone bromide (Relistor) in the US to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain. Thus, the presence of approved oral drugs is driving the market.
The Spain opioid-induced constipation market can be segmented by distribution channel into hospital pharmacies, online pharmacies, and retail pharmacies.
The hospital pharmacies segment is expected to grow at a high rate over the forecast period. The Spanish Society of Hospital Pharmacy (SEFH) is a national organization aiming to improve hospital pharmacy practice and healthcare system services. Strategic lines are focused on improving the efficiency and safety in the use of medication. In the Spain market, pharma companies promote their drugs through physicians and hospitals due to a lack of awareness among end-users about prescriptions. Further, according to the data by OECD, hospital pharmacies acquire 30% of the manufactured products directly from laboratories. However, for the Opioid-Induced Constipation drugs (OIC), more than 80% of the patients procure their drugs from hospital pharmacies.
Spain Opioid-Induced Constipation Market Competitive Landscape
The major players operating in the Spain opioid-induced constipation market are AstraZeneca, Shionogi & Company, Limited, Takeda Pharmaceuticals Company Ltd, and Bausch Health Companies Inc.
The key players are adopting various strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the growth of the Spain opioid-induced constipation market. For instance,
On June 19, 2019, Shionogi and Ferrer concluded a contract for the promotion in Spain of Rizmoic® (naldemedine), a therapeutic agent for opioid-induced constipation.
In April 2019, Shionogi licensed rights to BioDelivery Sciences International, Inc. to commercialize Symproic in the US. Under the terms of the transaction, Shionogi Inc. receives an upfront cash payment of $20 million, an additional $10 million in six months, as well as quarterly royalty payments.
In April 2019, Shionogi concluded a distribution contract with Sandoz for the sale of Rizmoic for the treatment of OIC in adult patients previously treated with a laxative in the key European markets of Germany, the UK, and the Netherlands, plus right of first refusal for certain other European markets.
In July 2016, Bausch Health Companies Inc launched RELISTOR Tablets to treat opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Frequently Asked Questions
What is the Projected CAGR value of the Spain Opioid-Induced Constipation Market?
Spain Opioid-Induced Constipation Market is expected to grow at a CAGR of 4.4% during the forecasting period 2022-2029.
Which region controlled the global market during 2022-2029?
North America region Controls the Spain Opioid-Induced Constipation Market during 2022-2029
Which is the fastest growing region in the Spain Opioid-Induced Constipation Market?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period